NCT04068246View on ClinicalTrials.gov

The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

February 28, 2021

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Metformin

1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly

DRUG

Placebo

Placebo tablet plus plus Methotrexate 7.5 mg weekly

Trial Locations (1)

13829

Faculty of Pharmacy, Shibīn al Kawm

All Listed Sponsors

lead

Sadat City University

OTHER

NCT04068246 - The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients | Biotech Hunter | Biotech Hunter